Publications - Year 7

• Chi KN, Zoubeidi A, Gleave ME. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs. 2008 Dec;17(12):1955-62. Review  PMID:19012510
  
  
  
• Clark JP, Munson, KW, Gu, JW, Lamparska-Kupsik K, Chan KG, Yoshida JS, Kawachi MH, Crocitto LE, Wilson TG, Fent, Z, Smith SS. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. Clin Chem. 2008, 54(12):2007-2017. PMID:18948370
  
  
  
• Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M. Insulin receptor expression by human prostate cancers. Prostate. 2009 Jan 1;69(1):33-40. PMID:18785179
  
  
  
• FitzGerald LM, Karlins E, Karyardi DM, Kwon EM, Stanford JL, Ostrander EA.  Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer and Prostatic Diseases 2009;12(2):192-7. PMID:18762813. NIHMS:71384
  
  
  
• FitzGerald LM, Kwon EM, Koopmeiners JS, Salinas CA, Stanford JL, Ostrander EA. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features.  Clinical Cancer Research 2009 May;15(9):3231-7. PMCID:PMC2707085
  
  
  
• FitzGerald LM. Agalliu I. Johnson K. Miller MA. Kwon EM. Hurtado-Coll A. Fazli L. Rajput AB. Gleave ME. Cox ME. Ostrander EA. Stanford JL. Huntsman DG.  Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.  BMC Cancer. 8:230, 2008.  PMCID:PMC2519091
  
  
  
• Gleave M, Klotz L, Taneja SS. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urol Oncol. 2009 Jan-Feb;27(1):81-6.  PMID:19111804
  
  
  
• Hadaschik BA, Zhang K, So AI, Bell JC, Thuroff JW, Rennie PS, Gleave ME. Oncolytic Vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer. Urologe A. 2008 Aug 2. [Epub ahead of print] German. PMID:18670747
  
  
  
• Harris WP, Mostaghel EA, Nelson PS, and Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009 Feb;6(2):76-85. PMID:19198621
  
  
  
• Hayashi N, Koller E, Fazli L, Gleave ME. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity. Prostate 2008 Sep 1;68(12):1283-95  PMID:18512732
  
  
  
• Holick CN, Stanford JL, Kwon E, Ostrander EA, Nejentsev S, Peters U.  Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16 (10):1990-99.  PMID:17932346, pre-dates PMC mandate
  
  
  
• Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biom Prev 2009 June;18(6):1929-33. PMID:19454612. NIHMS:1061040
  
  
  
• Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS and Luo J.  Ligand-independent androgen receptor variants derived from splicing of cryptic-exons signify hormone refractory prostate cancer.   Cancer Res 69:16-22, 2009. PMCID:PMC2614301
  
  
  
• Lin H, Feng F, Yu Y, Zheng Y, Shivapurkar N, Gazdar AF. Application of multidimensional selective item response regression model for studying multiple gene methylation in SV40 oncogenic pathways. Journal of American Statistical Association. 2008, 103(481), 201-211.
  
  
  
• Marks LS, Mostaghel EA, Nelson PS. Prostate tissue androgens: history and current clinical relevance. Urology. 2008 Aug;72(2):247-54. PMID:18502483
  
  
  
• McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Wright GL, Yasui Y, Zhang Z, Zhu L, Semmes J.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clinical Chemistry 2008;54:44-52. PMID:17981926.
  
  
  
• McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin D, Malik G, Oelschlager D, Partin A, Randolph T, Sokoll L, Srivistava S, Srivistava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes J.  SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clinical Chemistry 2008;54:53-60. PMID:18024530.
  
  
  
• McLerran DF, Feng Z, Semmes OJ, Cazares L, Randolph TW. Signal detection in high-resolution mass spectrometry data. Journal of Proteome Research 2008;7:276-285. PMID:18173224.
  
  
  
• Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol. 2009 Apr 20;27(12):2022-9. PMID:19289629
  
  
  
• Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M.  Circulating microRNAs as stable blood-based markers for cancer detection.  Proc Natl Acad Sci USA 105:10513-10518, 2008. PMCID:PMC2492472
  
  
  
• Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS and Vessella RL.  Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.  Clin Cancer Research 15:677-683, 2009. PMID:19147774
  
  
  
• Mostaghel EA, Nelson PS. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):243-58. PMCID:PMC2474812
  
  
  
• Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So AI, Gleave ME, Burt HM. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int. 2009 Apr;103(7):978-86. PMID:19007363
  
  
  
• Muramaki M, So A, Hayashi N, Sowery R, Miyake H, Fujisawa M, Gleave ME. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int. 2009 Feb;103(3):384-90. PMID:19007378
  
  
  
• Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, Kim Y, Gleave ME. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res. 2008 Sept 15; 14(18):5769-77. PMID:18794086
  
  
  
• Parsons JK, Saria EA, Nakayama M, Vessella RL, Sawyers CL, Isaacs WB, Faith DA, Bova GS, Mitchell R and De Marzo AM.  Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells.   Prostate 2009 Apr;69:559-569. PMID:19142959
  
  
  
• Peacock JW, Palmer J, Fink D, Ip S, Pietras EM, Mui AL, Chung SW, Gleave ME, Cox ME, Parsons R, Peter ME, Ong CJ. PTEN loss promotes mitochondrially dependent type II Fas-induced apoptosis via PEA-15. Mol Cell Biol. 2009 Mar;29(5):1222-34. PMCID:PMC2643821
  
  
  
• Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clinical Cancer Research 2009 May;15(9):3223-30. PMID:19366828.  NIHMS:pending
  
  
  
• Pepe MS, Feng Z, Gu JW.  Invited commentary on ‘Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond.’ Statistics in Medicine 2008;27:173–181, 2008. PMID:17671958.
  
  
  
• Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. JNCI. 2008, 100, 1432-1438. PMC:PMCID2567415.
  
  
  
• Pepe MS, Feng Z, Longton G, Koopmeiners J. Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility. Statistics in Medicine. 2009: 28:762-779. PMID:19097251
  
  
  
• Qian DZ, Huang CY, O'Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, R Vessella, Lange PH, Nelson PS, Beer TM. Prostate cancer-associated gene expression alterations determined from needle biopsies. Clin Cancer Res 2009 May;15(9):3135-42. PMID:19366833
  
  
  
• Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL and Visakorpi T. TMPRSS2:ERG fusion identifies a subpopulation of prostate cancers with a favorable prognosis. Clin Cancer Res 14:3395-3400, 2008.
  
  
  
• Schayek, H., Haugk, K., Sun, S., True, L.D., Plymate, S.R., Werner, H. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor-I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res. 2009 Mar 1;15(5):1558-65. Epub 2009 Feb 17. PMID:19223505
  
  
  
• Siva AC, Nelson LJ, Fleischer CL, Majlessi M, Becker MM, Vessella RL, Reynolds MA.  Molecular assays for the detection of microRNAs in prostate cancer.  Mol Cancer 2009 Mar 6;8:17. PMCID:PMC2656451
  
  
  
• Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.  Clin Cancer Res. 2009 Jan 1;15(1):39-47. PMID:19118031
  
  
  
• Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW . [-2]proenzyme prostate specific antigen for prostate cancer detection: a National Cancer Institute early detection research network validation study. Journal of Urology. 2008, 180(2):539-543. PMC:PMCID2647141
  
  
  
• Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB, Tucker SJ, Martinez SR, Mizuno R,Singer FR, Hoon D.  A multimarker circulating DNA assay for assessing prostate cancer patient’s blood.  Clin Chem 2009 55(3):559-567. PMID:19131636
  
  
  
• Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin LL, DeWeese TL, Scardino PT, Stephenson AJ, Pollack A. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.  Urology. 2008 Dec;72(6):1298-302; discussion 1302-4. PMID:18672274
  
  
  
• True LD, Hawley S, Norwood TH, Braun KR, Evanko SP, Chan CK, LeBaron RC, Wight TN. The accumulation of versican in the nodules of benign prostatic hyperplasia. Prostate 2009 Feb;69:149-158. PMID:18819099
  
  
  
• True LD. Quality control in molecular immunohistochemistry. Histochem Cell Biol 2008 Sep; 130:473-480. PMCID:PMC2522330
  
  
  
• Viaio DD, Kim J, Hager MH, Morello M, Yang W, True L, Rubin MA, Adam RM, Beroukhim R, Freeman MR. Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease. Can Res 2009 (in press).
  
  
  
• Wang G, Haile S, Comuzzi B, Tien AH, Wang J, Yong TM, Jelescu-Bodos AE, Blaszczyk N, Vessella RL, Masri BA and Sadar MD.  Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression.  Cancer Res 2009 Apr 15;69(8):3433-42. PMID:19351846
  
  
  
• Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, Bittinger F, Thuroff JW, Vessella RL, Cher ML, Bonfil RD. C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia 10:996-1003; 2008. PMC:PMCID2517645
  
  
  
• Wu JD, Lin DW, Page ST, Lundgren AD, True LD, Plymate SR. Activation of two DNA damage surveillance pathways in benign prostate tissues biopsied for cause. Transl Oncol 2009 (in press). PMC Journal – In Process.
  
  
  
• Wu, J.D., C.L. Atteridge, X. Wang, T. Seya, S. R. Plymate. Obstructing shedding of the immune stimulatory MICB prevents tumor formation – implication for targeted cancer therapy. Clinical Cancer Research 2009;15:632-40.
  
  
  
• Wu, JD Lin, DW Atteridge, CL Page, ST True, LD, Plymate, SR. Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer. Transl Oncol. 2009 Mar;2(1):39-45. PMCID:PMC2647707
  
  
  
• Zhang X, Wang W, True LD, Vessella RL and Takayama TK.  Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastases.  Prostate 2009 May15;69(7):727-36. PMCID:PMC2720055

Book Chapters

• Feng Z, Kagan J, Srivastava S. Towards a robust system for biomarker triage and validations – EDRN experience. Chapter 21, Prostate Cancer Screening, 2nd edition.  eds.  DP Ankerst, C Tangen, IM Thompson. 2009. Human Press.

Meetings

• Higano C, Saad F, Somer B, Curti B, Petrylak D, Drake CG, Schnell F, Redfern CH, Schrijvers D, Sacks N.  A phase 3 trial of GVAX immunotherapy for prostate cancer vs. docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. 2009 Genitourinary Cancers Symposium: A multidisciplinary approach, Orlando, FL, Feb 26-28, 2009.
  
   
• Higano CS, Alumkal J, Ryan CJ, Yu EY, Beer TM, Chandrawansa K, Katz T, Youssoufian H, Schwartz J, Prostate Cancer Clinical Trials Consortium.  A phase 2 study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody against the insulin-like growth factor-I receptor, as monotherapy in patients with metastatic, asymptomatic castrate resistant prostate cancer.  2009 ASCO Annual Meeting, Orlando, FL, May 29-June 2, 2009.
  
  
  
• Hotte SJ, Yu EY, Hirte HW, Higano CS, Gleave M, Chi KN.  OGX-427, a 2'methoxyethyl antisense oligonucleotide against HSP27: results of a first-in human trial.  2009 ASCO Annual Meeting, Orlando, FL, May 29-June 2, 2009.
  
  
  
• Rademacher BL, Garzotto M, Higano CS, O'Brien CA, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM.  Five-year relapse-free survival and predictors of relapse following pre-operative docetaxel and mitoxantrone for high-risk localized prostate cancer.  2009 ASCO Annual Meeting, Orlando, FL, May 29-June 2, 2009.
  
  
  
• Rothenberg ML, Poplin E, Mehnert J, LoRusso P, Fox F, Schwartz J, Rowinsky E, Higano C.  Pharmacokinetic and pharmacodynamic results of phase 1 studies of IMC-A12, a recombinant human insulin-like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies. 20th EORTC-NCI-AACR symposium on "Molecular targets and cancer therapeutics", Geneva, Switzerland Oct 21-24, 2008.
  
  
  
• Schellhammer PF, Higano CS, Berger ER, Shore ND, Small EJ, Penson DF, Sims RB, Yuh L, Frohlich MW, Kantoff PW, for the IMPACT Study Investigators.  A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma.  2009 ASCO Annual Meeting, Orlando, FL, May 29-June 2, 2009.
  
  
  
• Scher HI, Beer T, Higano C, Efstathiou E, Anand A, Hirmand M, Hung D, Larson S, Fleisher M, Sawyers C.  Clinical study of MDV3100 in progressive castration-resistant prostate cancer.  2009 AUA Annual Meeting, Chicago, IL, April 25-30, 2009.
  
  
  
• Scher HI, Beer T, Higano CS, Efstathiou E, Shelky J, Hirmand M, Hung D, Anand A, Larson S, Fleisher Sawyers CL.  Phase 1-2 study of MDV3100 in castration-resistant prostate cancer. 2009 Genitourinary Cancers Symposium: A multidisciplinary approach, Orlando, FL, Feb 26-28, 2009.
  
  
  
• Scher HI, Beer TM, Higano CS, Taplin M, Efstathiou E, Anand A, Hung D, Hirmand M, Fleisher M, The Prostate Cancer Clinical Trials Consortium.  Anitumor activity of MDV3100 in a Phase 1-2 study of castration-resistant prostate cancer.  2009 ASCO Annual Meeting, Orlando, FL, May 29-June 2, 2009.
  
  
  
• Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Hudes GR, Cheng S, Paliwal P, Sternberg CN. Dasatinib in patients with hormone-refractory progressive prostate cancer: a phase II study. Poster presentation at 2008 Prostate Cancer Foundation Scientific Symposium, Lake Tahoe, NV.  October 16, 2008.